GlassScriptPhysician profile
Christine Son
NPI 1568996379
$2,372.26
in general payments reported to CMS, 2019-2025
36 companies · $1,671 in 2025
The $1,671 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $37.80 · 2023: $305 · 2024: $358 · 2025: $1,671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,234 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,233.82 |
| Education | $100.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $236.79 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $188.57 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $183.07 | 2025 | Tagrisso, Enhertu |
| Stryker Corporation | $162.64 | 2025 | Optablate |
| Pfizer INC. | $155.50 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $149.47 | 2022-2025 | Keytruda, Keytruda Qlex, Welireg |
| Sobi, INC | $124.95 | 2024-2025 | |
| Glaxosmithkline, LLC. | $76.56 | 2025 | Ojjaara, Blenrep, Jemperli |
| Janssen Biotech, INC. | $73.64 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Takeda Pharmaceuticals U.S.A., INC. | $72.39 | 2024-2025 | Iclusig, Fruzaqla |
| Daiichi Sankyo INC. | $71.21 | 2025 | Enhertu, Datroway |
| Seagen INC. | $69.99 | 2023 | |
| Recordati_rare_diseases_inc. | $63.38 | 2025 | Enjaymo |
| Acrotech Biopharma INC. | $63.26 | 2023-2025 | Beleodaq, Ryzneuta |
| Amgen INC. | $58.11 | 2022-2024 | Lumakras |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $56.24 | 2025 | |
| Eisai INC. | $55.91 | 2025 | |
| Genentech USA, INC. | $54.93 | 2024-2025 | Venclexta, Polivy, Columvi |
| Bayer Healthcare Pharmaceuticals INC. | $54.53 | 2025 | |
| Beone Medicines USA, INC. | $45.41 | 2025 | Brukinsa, Tevimbra |
| Geron Corporation | $38.64 | 2025 | Rytelo |
| Regeneron Healthcare Solutions, INC. | $28.89 | 2025 | Libtayo |
| Emd Serono, INC. | $27.90 | 2025 | |
| Adc Therapeutics America, INC. | $25.79 | 2024 | |
| Rigel Pharmaceuticals, INC. | $24.98 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Gilead Sciences, INC. | $22.22 | 2025 | Trodelvy |
| Stemline Therapeutics INC. | $22.01 | 2025 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $21.41 | 2024 | Onivyde |
| Celgene Corporation | $21.33 | 2023 | Pomalyst |
| Lilly USA, LLC | $20.21 | 2024 | Verzenio, Jaypirca |
| Legend Biotech USA INC. | $19.82 | 2025 | Carvykti |
| Servier Pharmaceuticals LLC | $18.77 | 2025 | |
| Springworks Therapeutics, INC. | $18.54 | 2025 | Ogsiveo |
| Array Biopharma INC | $17.50 | 2025 | Mektovi, Tukysa, Braftovi |
| Fennec Pharmaceuticals, INC. | $13.88 | 2025 | Fyarro |
| Dendreon Pharmaceuticals LLC | $13.82 | 2024 | Provenge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Son listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.